Long-Acting Injectable PrEP for HIV Prevention in Europe
In April 2026, French health authorities announced that Vocabria (cabotegravir) and Rekambys (rilpivirine), long-acting injectable HIV pre-exposure prophylaxis (PrEP) regimens, became reimbursable for adolescents aged 12 to 17, marking a ... Read More